Home › Non-Small Cell Lung Cancer › NCT07028489
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
INCLUSION CRITERIA * Be ≥18 years of age at the time of informed consent * Evidence of a confirmed diagnosis of EGFR mutant (EGFR exon 19del or EGFR exon 21 L858R) locally advanced or metastatic NSCLC diagnosed on Jan 1st 2024 or later. EXCLUSION CRITERIA * ECOG≥2 at diagnosis of advanced or metastatic NSCLC * Evidence of prior treatment with osimertinib, amivantamab or lazertinib. For the planned selection and analysis of external controls, further eligibility criteria will be applied according to the COPERNICUS SAP.
About the study
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
Sponsor: N-Power Medicine · Participants: 130 · Started: Jun 5, 2025
Contact the study team
- N-Power Medicine Support · Phone: 1-833-467-6734
Official record on ClinicalTrials.gov — NCT07028489
Locations in the U.S.
| California | Pacific Cancer Care, Monterey Torrance Memorial Physician Network-Cancer Care, Torrance John Muir Health, Walnut Creek |
| Delaware | Bayhealth Cancer Center- Kent, Dover Bayhealth Cancer Center- Sussex, Milford |
| Idaho | Kootenai Clinic Cancer Services Coeur d'Alene, Coeur d'Alene |
| Illinois | Northwest Oncology & Hematology, Elk Grove Village |
| New Mexico | New Mexico Oncology Hematology Consultants, Albuquerque |
| Pennsylvania | Lankenau Medical Center, Paoli (Not yet recruiting) |
| Texas | Oncology Consultants, P.A., Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.